CHANGES IN THE INCIDENCE AND OVERALL SURVIVAL OF PATIENTS WITH
MYELOPROLIFERATIVE NEOPLASMS BETWEEN 2002 AND 2016 IN THE UNITED
POSTER 31
STATES
S
rdan Verstovsek1, Jingbo Yu2, Robyn M. Scherber2, Sumit Verma3, Christopher Dieyi3 and Shreekant
Parasuraman2
(1)The University of Texas MD Anderson Cancer Center, Leukemia Department, Houston
(2)Incyte Corporation, Wilmington
(3)STATinMED Research, Plano
Objective
Contemporary analyses of myeloproliferative neoplasm (MPN) incidence and patient survival
are needed, as the most recent available real-world analyses were conducted on time periods
up to 2012. The objective of this analysis was to describe trends in incidence and overall
survival (OS) among patients with MPNs, including polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis (PMF), in the United States using data
through 2016 from the Surveillance, Epidemiology, and End Results (SEER) database.
Methods
Adult patients with PV, ET, or PMF were identified from the SEER 18 registry (2002–2016)
using the primary site of bone marrow (C421) and International Classification of Diseases for
Oncology (ICD-O) histology codes (ICD-O-3: 9950 PV, 9962 ET, and 9961 PMF). Patients
aged <18 years on the index date (date of diagnosis) or with missing demographic or survival
information were excluded. Age-adjusted incidence rates (per 100,000 person-years) were
standardized to the 2000 US population by dividing the incidence rates among adult patients
per year by the adult US population in the year 2000. Confidence intervals for rates and rate
ratios were calculated using the Tiwari method (Tiwari et al. Stat Methods Med Res.
2006;156:547). Kaplan-Meier methodology was used to compare mortality rates by
diagnosis year, categorized into 3 groups: 2002–2006, 2007–2011, and 2012–2016. Patients
were censored at the end of each 5-year analysis timeframe.
Results
Data for 34,031 patients (mean age, 65 y; female, 50.5%) were included in this analysis (PV,
n=15,141; ET, n=14,676; PMF, n=4214). Over the entire study period, incidence rates (95% CI)
for PV, ET, and PMF were 1.57 (1.55–1.60), 1.55 (1.52–1.57), and 0.44 (0.43–0.45) per 100,000
person-years, respectively. The annual incidence rates of PV and PMF were higher for male vs
female patients (1.94 vs 1.23 and 0.59 vs 0.33, respectively); however, the ET incidence rate
was higher for female patients (1.73 vs 1.34; Table 1). ET incidence increased across the 3 time
periods, whereas PV and PMF incidence remained relatively stable.
Over the 3 time periods, mortality rates decreased for PV and PMF but not for ET (Table 2).
Improved OS was observed in patients with PMF over time (median 95% CI: 2002–2006, 3.3
2.4–3.6 y; 2007–2011, 3.6 3.3–4.3 y; 2012–2016, 3.8 3.5–4.2 y). The median (95% CI) OS
for the entire time period investigated was 12.0 (11.7–12.4) years for patients with PV, 12.0
(11.7–12.3) years for those with ET, and 3.6 (3.4–3.8) years for patients with PMF.